Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TIL
Upturn stock ratingUpturn stock rating

Instil Bio Inc. (TIL)

Upturn stock ratingUpturn stock rating
$23.43
Last Close (24-hour delay)
Profit since last BUY11.47%
upturn advisory
WEAK BUY
BUY since 30 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/08/2025: TIL (4-star) is a WEAK-BUY. BUY since 30 days. Profits (11.47%). Updated daily EoD!

Upturn Star Rating

rating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

rating

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $118.67

1 Year Target Price $118.67

Analysts Price Target For last 52 week
$118.67 Target price
52w Low $9.7
Current$23.43
52w High $92

Analysis of Past Performance

Type Stock
Historic Profit 214.61%
Avg. Invested days 34
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/08/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 155.08M USD
Price to earnings Ratio -
1Y Target Price 118.67
Price to earnings Ratio -
1Y Target Price 118.67
Volume (30-day avg) 4
Beta 2.28
52 Weeks Range 9.70 - 92.00
Updated Date 07/8/2025
52 Weeks Range 9.70 - 92.00
Updated Date 07/8/2025
Dividends yield (FY) -
Basic EPS (TTM) -11.97

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -12.59%
Return on Equity (TTM) -44.5%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 138092674
Price to Sales(TTM) 55329.79
Enterprise Value 138092674
Price to Sales(TTM) 55329.79
Enterprise Value to Revenue 43213.95
Enterprise Value to EBITDA 0.62
Shares Outstanding 6559930
Shares Floating 2649948
Shares Outstanding 6559930
Shares Floating 2649948
Percent Insiders 6.51
Percent Institutions 80.57

ai summary icon Upturn AI SWOT

Instil Bio Inc.

stock logo

Company Overview

overview logo History and Background

Instil Bio Inc. is a biopharmaceutical company focused on developing adoptive cell therapies for the treatment of cancer. Founded in 2018, it went public in 2021. The company aims to use its expertise in tumor-infiltrating lymphocyte (TIL) therapies to address unmet medical needs in cancer treatment.

business area logo Core Business Areas

  • TIL Therapy Development: Developing and commercializing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors.
  • Manufacturing and Process Development: Enhancing the manufacturing process for TIL therapies to improve efficacy and scalability.
  • Research and Development: Conducting preclinical and clinical research to discover and develop next-generation TIL therapies.

leadership logo Leadership and Structure

The company is led by CEO Bronson Moore. The organizational structure includes departments focused on research and development, clinical operations, manufacturing, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • ITIL-168 (Lead Candidate): ITIL-168 is Instil Bio's lead TIL therapy candidate, targeting advanced melanoma. It is currently in clinical trials. There is no public data on the market share or revenue for ITIL-168, as it is still in development. Competitors include Iovance Biotherapeutics (IOVA) and other companies developing cell therapies for melanoma.
  • Other TIL Programs: Instil Bio has other TIL therapy programs in preclinical and early clinical development targeting other solid tumors. There is no public data on the market share or revenue for this. Competitors include other cell therapy companies, as well as companies developing traditional cancer treatments.

Market Dynamics

industry overview logo Industry Overview

The cell therapy market is growing rapidly, driven by advances in immunotherapy and personalized medicine. There is significant unmet need for effective treatments for solid tumors.

Positioning

Instil Bio is positioned as a developer of next-generation TIL therapies, with a focus on improving manufacturing and scalability. It aims to address the limitations of first-generation TIL therapies.

Total Addressable Market (TAM)

The TAM for cell therapies in oncology is estimated to be in the tens of billions of dollars. Instil Bio is positioned to capture a portion of this market with its TIL therapy platform, pending successful clinical trials and regulatory approvals.

Upturn SWOT Analysis

Strengths

  • Proprietary TIL therapy platform
  • Experienced management team
  • Focus on improving TIL manufacturing
  • Pipeline of TIL therapy candidates

Weaknesses

  • Clinical stage company with no approved products
  • High cash burn rate
  • Dependence on successful clinical trial outcomes
  • Competition from other cell therapy companies

Opportunities

  • Potential to address unmet needs in solid tumor treatment
  • Expansion of TIL therapy platform to new indications
  • Partnerships with larger pharmaceutical companies
  • Advancements in TIL manufacturing technologies

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from other therapies
  • Reimbursement challenges

Competitors and Market Share

competitor logo Key Competitors

  • IOVA
  • NK
  • CRBU

Competitive Landscape

Instil Bio competes with other cell therapy companies developing treatments for cancer. Its advantages include its proprietary TIL therapy platform and focus on improving manufacturing. Disadvantages include its clinical stage and high cash burn rate.

Growth Trajectory and Initiatives

Historical Growth: The company's growth has been driven by its progress in developing TIL therapy candidates and securing funding.

Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its TIL therapies. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include advancing ITIL-168 through clinical trials, improving TIL manufacturing processes, and expanding its pipeline of TIL therapy candidates.

Summary

Instil Bio is a clinical-stage biopharmaceutical company developing TIL therapies for solid tumors. The company's success hinges on the success of its clinical trials, particularly ITIL-168. The company has a strong platform and focus on improving manufacturing but is exposed to high cash burn and fierce competition. Investors should monitor clinical trial data and regulatory developments closely.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Data may be outdated. Consult a financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Instil Bio Inc.

Exchange NASDAQ
Headquaters Dallas, TX, United States
IPO Launch date 2021-03-19
Chairman & CEO Mr. Bronson Crouch
Sector Healthcare
Industry Biotechnology
Full time employees 14
Full time employees 14

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.